Real-Time Surveillance of New Anticancer Therapies in the National Veterans Affairs System
The Veterans Affairs (VA) system is the largest integrated health system in the US, with one of the world's longest-running electronic medical record (EMR) systems. We describe the potential of VA EMR data for real-time surveillance of efficacy, toxicity, and uptake of new therapies in oncology...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 111; no. 3; p. e431 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.11.2021
|
Online Access | Get full text |
Cover
Loading…
Abstract | The Veterans Affairs (VA) system is the largest integrated health system in the US, with one of the world's longest-running electronic medical record (EMR) systems. We describe the potential of VA EMR data for real-time surveillance of efficacy, toxicity, and uptake of new therapies in oncology. As a case study, we describe the implementation of durvalumab for adjuvant treatment of stage III non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiation (CRT) after publication of the landmark PACIFIC trial in 2017.
We used the Veterans Affairs Informatics and Computing Infrastructure (VINCI) to identify all intravenous administrations of durvalumab from November 2017 to January 2021 among patients with at least one inpatient or outpatient lung cancer ICD-10 diagnosis code. Cancer stage and tumor histology were algorithmically extracted from physician notes and reviewed for accuracy. Radiation therapy dates and concurrent chemotherapy delivery were ascertained through outpatient CPT codes for radiation delivery and intravenous chemotherapy infusion records. Overall survival (OS) was obtained from the VA Vital Status File (updated on a quarterly basis) and from the VA Master Patient Index (updated on a daily basis). Date of radiographic progression were obtained through physician review of extracted CT and PET scan reports. Demographic, staging, and treatment information were supplemented with VA Central Cancer Registry information where available. Statistics were performed with statistical analysis software.
We identified 1106 patients with stage III NSCLC (60% stage IIIA, 35% IIIB, and 3% IIIC) treated with upfront CRT who received at least one adjuvant durvalumab infusion, of whom only 135 (12%) were represented in cancer registry data. The median age was 69 years and 95% were male. Eighty-six percent reported current or former tobacco use, and the cohort was evenly split between adenocarcinoma (48%) and squamous cell histology (48%). Patients received a median of 6 durvalumab infusions (IQR 3 to 15) over a median of 154 days (IQR 35 to 308 days). Compared to patients enrolled in the PACIFIC trial, veterans received a lower number of durvalumab infusions (6 vs. 14) and had a higher rate of systemic steroid initiation for possible immune-related toxicity (43% vs 20%). Three-year progression-free survival was 32.5% (95% CI 25% to 40%). Three-year OS was 51% (95% CI 46% to 56%) compared to 57% in PACIFIC.
Veterans received fewer adjuvant durvalumab infusions than in the PACIFIC trial but maintained comparable survival. National VA administrative data, which are largely updated on a daily or weekly basis, are a unique resource to study real-time implementation of new therapies in large national cohorts. Improved case-finding algorithms are necessary to capture patients not included in the VA Central Cancer Registry. |
---|---|
AbstractList | The Veterans Affairs (VA) system is the largest integrated health system in the US, with one of the world's longest-running electronic medical record (EMR) systems. We describe the potential of VA EMR data for real-time surveillance of efficacy, toxicity, and uptake of new therapies in oncology. As a case study, we describe the implementation of durvalumab for adjuvant treatment of stage III non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiation (CRT) after publication of the landmark PACIFIC trial in 2017.
We used the Veterans Affairs Informatics and Computing Infrastructure (VINCI) to identify all intravenous administrations of durvalumab from November 2017 to January 2021 among patients with at least one inpatient or outpatient lung cancer ICD-10 diagnosis code. Cancer stage and tumor histology were algorithmically extracted from physician notes and reviewed for accuracy. Radiation therapy dates and concurrent chemotherapy delivery were ascertained through outpatient CPT codes for radiation delivery and intravenous chemotherapy infusion records. Overall survival (OS) was obtained from the VA Vital Status File (updated on a quarterly basis) and from the VA Master Patient Index (updated on a daily basis). Date of radiographic progression were obtained through physician review of extracted CT and PET scan reports. Demographic, staging, and treatment information were supplemented with VA Central Cancer Registry information where available. Statistics were performed with statistical analysis software.
We identified 1106 patients with stage III NSCLC (60% stage IIIA, 35% IIIB, and 3% IIIC) treated with upfront CRT who received at least one adjuvant durvalumab infusion, of whom only 135 (12%) were represented in cancer registry data. The median age was 69 years and 95% were male. Eighty-six percent reported current or former tobacco use, and the cohort was evenly split between adenocarcinoma (48%) and squamous cell histology (48%). Patients received a median of 6 durvalumab infusions (IQR 3 to 15) over a median of 154 days (IQR 35 to 308 days). Compared to patients enrolled in the PACIFIC trial, veterans received a lower number of durvalumab infusions (6 vs. 14) and had a higher rate of systemic steroid initiation for possible immune-related toxicity (43% vs 20%). Three-year progression-free survival was 32.5% (95% CI 25% to 40%). Three-year OS was 51% (95% CI 46% to 56%) compared to 57% in PACIFIC.
Veterans received fewer adjuvant durvalumab infusions than in the PACIFIC trial but maintained comparable survival. National VA administrative data, which are largely updated on a daily or weekly basis, are a unique resource to study real-time implementation of new therapies in large national cohorts. Improved case-finding algorithms are necessary to capture patients not included in the VA Central Cancer Registry. |
Author | Bryant, A.K. Sankar, K. Green, M. Ramnath, N. |
Author_xml | – sequence: 1 givenname: A.K. surname: Bryant fullname: Bryant, A.K. organization: Department of Radiation Oncology, University of Michigan, Ann Arbor, MI – sequence: 2 givenname: K. surname: Sankar fullname: Sankar, K. organization: Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI – sequence: 3 givenname: N. surname: Ramnath fullname: Ramnath, N. organization: Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI – sequence: 4 givenname: M. surname: Green fullname: Green, M. organization: Department of Radiation Oncology, University of Michigan, Ann Arbor, MI |
BookMark | eNqFkF9LwzAUxYNMcJt-BCFfoDU3XZr2ScbwH4wJbor4EtL0hqV07UjqZN_elvru04V77zmc85uRSdM2SMgtsBgYpHdV7CrfFseYMw4xkzFwnl6QKWQyjxIhPidkypKURUn_fUVmIVSMMQC5mJKvN9R1tHMHpNtvf0JX17oxSFtLN_hDl03nzLDwdLdHr48OA3UN7fZIN7pzbaNr-oFdf2oCXVqrnQ90ew4dHq7JpdV1wJu_OSfvjw-71XO0fn16WS3XkeGQpxE3IsfU6kxKnqIsIEE0RmhrFhnPbQa8LLTIyrLgIHPGEp0WmRWQc1nyAlgyJ2L0Nb4NwaNVR-8O2p8VMDUAUpUaAakBkGJSDYB63f2owz7cyaFXwTjsu5bOo-lU2bp_HH4Ba21zgw |
ContentType | Journal Article |
Copyright | 2021 |
Copyright_xml | – notice: 2021 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.ijrobp.2021.07.1226 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
EndPage | e431 |
ExternalDocumentID | 10_1016_j_ijrobp_2021_07_1226 S0360301621020964 |
GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 7-5 AAEDT AAEDW AAIAV AALRI AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ADBBV AENEX AEVXI AFCTW AFRHN AFTJW AGZHU AHHHB AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS ALXNB AMRAJ BELOY DU5 EBS EFJIC F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 O9- OC~ OO- RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ZA5 ~S- .55 .GJ 29J 5VS AAQFI AAQQT AAQXK AAYXX ABEFU ADMUD ADPAM ADVLN AFFNX AFJKZ AGRDE AKRWK ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB FIRID G-2 HMK HVGLF HX~ HZ~ NQ- R2- RIG SAE SEW UDS X7M XPP ZGI |
ID | FETCH-LOGICAL-c2196-2c59e6fa87726e7b13eecc5afc4829f812dba58ddb2179003a6b8f51927d2b103 |
ISSN | 0360-3016 |
IngestDate | Thu Sep 26 19:19:45 EDT 2024 Fri Feb 23 02:40:57 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2196-2c59e6fa87726e7b13eecc5afc4829f812dba58ddb2179003a6b8f51927d2b103 |
OpenAccessLink | http://www.redjournal.org/article/S0360301621020964/pdf |
ParticipantIDs | crossref_primary_10_1016_j_ijrobp_2021_07_1226 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2021_07_1226 |
PublicationCentury | 2000 |
PublicationDate | 2021-11-01 2021-11-00 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0001174 |
Score | 2.421335 |
Snippet | The Veterans Affairs (VA) system is the largest integrated health system in the US, with one of the world's longest-running electronic medical record (EMR)... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | e431 |
Title | Real-Time Surveillance of New Anticancer Therapies in the National Veterans Affairs System |
URI | https://dx.doi.org/10.1016/j.ijrobp.2021.07.1226 |
Volume | 111 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFeEFcxxpAfeE2I7ThOHyfENFGNh7JBxUtkp47UItIp6kDwf_ifOye2c4EKwV6iNlLaxOfLuXw55wshr6zIKqVWcKdJg9RNKSPNrI6SCrW-BRdZ-yjm_H12dpm-W8rlZPJr0LV0vTNx-XPvXMltrAr7wK44Jfsflu1-FHbAZ7AvbMHCsP0nGy8gy4twiAPu_-abxRcI4X2KJID9jroA6ONK22BfRaOv1m3zlWtrDBzgR2yHgXAVHu14CfNhzjomDQdSEw3qGriMsy67qRfTD8A42qQn4psf2sscxPO443Z0_cV1eff7FvorkvpuFGzUItQSuPGQq-DMD-11BFoYohn1eEIMhVCQMK-I7fxwrmYRpELLkaP2bnk9LORbt2tTH0rs6Osf4cExFZt4vWm2BtVKOUPpVsb5b3LcbYD_gGeGJ4ZlMZR66R1ywNVMyik5OJkvPs27kM-83He4kn5U7PXeP9ufBA0Sm4sH5L6vSOiJg9dDMrH1I3L33PdcPCafO5TRIcrotqKAMtqjjHYoo-uaAspoQBkNKKMeZdSh7Am5PH178eYs8m_kiEqIbFnESzmzWaVzqMkyqwwTFlyA1FWZ5nxWQbK4Mlrmq5XhqPyWCJ2ZvIIigYM7MCwRT8m03tb2GaEiU0ZAecC0NUhom1JaYVSuVZIyZfQhicMSFVdOeKUIHYmbwq1pgWtaJKrANT0keVjIwmePLisswPp_P_T57Q89Ivd6oL8g011zbY8hTd2Zlx4kN7tOkmc |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-Time+Surveillance+of+New+Anticancer+Therapies+in+the+National+Veterans+Affairs+System&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Bryant%2C+A.K.&rft.au=Sankar%2C+K.&rft.au=Ramnath%2C+N.&rft.au=Green%2C+M.&rft.date=2021-11-01&rft.pub=Elsevier+Inc&rft.issn=0360-3016&rft.eissn=1879-355X&rft.volume=111&rft.issue=3&rft.spage=e431&rft.epage=e431&rft_id=info:doi/10.1016%2Fj.ijrobp.2021.07.1226&rft.externalDocID=S0360301621020964 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0360-3016&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0360-3016&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0360-3016&client=summon |